Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Bruck W, Lucchinetti C, Schmidbauer M, Jellinger K, Lassmann H (2003) Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 62:25–33
Avramut M, Achim CL (2003) Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem 3:1376–1382
Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M, Schroder R, Deckert M, Schmidt S, Ravid R, Rajewsky K (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active MS lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192:393–404
Besser M, Wank R (1999) Clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 162:6303–6306
Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125:1297–1308
Butzkueven H, Zhang J-G, Soilu-Hänninen M, Hochrein H, Chionh F, Shipham KA, Emery B, Turnley AM, Petratos S, Ernst M, Bartlett PF, Kilpatrick TJ (2002) LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 8:613–619
Cohen IR (1992) The cognitive paradigm and the immunological homunculus. Immunol Today 13:490–494
De Keyser J, Sulter G, Luiten PG (1999) Clinical trials with neuroprotective drugs in acute ischemic stroke: arewe doing the right thing? TrendsNeurosci 22:535–540
Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393–399
Flügel A, Willem M, Berkowicz T, Wekerle H (1999) Gene transfer into CD4+ T lymphocytes: Green fluorescent protein engineered, encephalitogenic T cells used to illuminate immune responses in the brain. NatMed 5:843–847
Giess R, Maurer M, Linker R, Gold R, Warmuth-Metz M, Toyka KV, Sendtner M, Rieckmann P (2002) Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol 59:407–409
Guo X, Dillman JF, III, Dawson VL, Dawson TM (2001) Neuroimmunophilins: novel neuroprotective and neuroregenerative targets. Ann Neurol 50:6–16
Hemmer B, Archelos JJ, Hartung H-P (2002) Newconcepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3:291–301
Hohlfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120:865–916
Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H (2000) The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis. J Neuroimmunol 107:161–166
Jacobsen M, Cepok S, Quak E, Happel M, Gaber R, Ziegler A, Schock S, Oertel WH, Sommer N, Hemmer B (2002) Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 125:538–550
Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH (2002) The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 8:532–533
Kerschensteiner M, Gallmeier E, Behrens L, Klinkert WEF, Kolbeck R, Hoppe E, Stadelmann C, Lassmann H, Wekerle H, Hohlfeld R (1999) Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: A neuroprotective role of inflammation? J Exp Med 189:865–870
Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R (2003) Neurotrophic cross-talk between the nervous and immune systems: Implications for neurological diseases. Ann Neurol 53:292–304
Kornek B, Lassmann H (1999) Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 9:651–656
Kramer R, Zhang Y, Gehrmann J, Gold R, Thoenen H, Wekerle H (1995) Gene transfer through the blood-nerve barrier: Nerve growth factor engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat Med 1:1162–1166
Lassmann H (2003) Axonal injury in multiple sclerosis. J Neurol Neurosurg Psych 74:695–697
Lewin GR, Barde Y-A (1996) Physiology of the neurotrophins. Annu Rev Neurosci 19:289–317
Linker RA, Mäurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, Gold R (2002) CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8:620–624
Meinl E, Hoch RM, Dornmair K, De Waal Malefijt R, Bontrop RE, Jonker M, Lassmann H, Hohlfeld R, Wekerle H, ’t Hart BA (1997) Encephalitogenic potential ofmyelin basic protein-specificTcells isolated from normal rhesus macaques. AmJ Pathol 150:445–453
Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M(1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 5:49–55
Neumann H, Medana IM, Bauer J, Lassmann H (2002) Cytotoxic Tlymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 25:313–319
Noseworthy JH, Gold R, Hartung H-P (1999) Treatment of multiple sclerosis: Recent trial and future perspectives. Curr Opin Neurol 12:279–293
Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID (2002) Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 51:215–223
Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR (1999) Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci 22:295–299
Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, Rajewsky K, Wekerle H, Hohlfeld R, Goebels N (2004) Multiple sclerosis: Brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci 101:2428–2433
Smith KJ, Lassmann H (2002) The role of nitric oxide in multiple sclerosis. Lancet Neurology 1:232–241
Torcia M, Bracci-Laudiero L, Lucibello M, Nencioni L, Labardi D, Rubatelli A, Cozzolino F, Aloe L, Garaci E (1996) Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 85:345–356
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mørk S, Bø L (1998) Axonal transection in the lesion of multiple sclerosis. N Engl J Med 338:278–285
Ziemssen T, Kumpfel T, Klinkert WEF, Neuhaus O, Hohlfeld R (2002) Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain 125:2381–2391
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Hohlfeld, R., Kerschensteiner, M., Stadelmann, C., Lassmann, H., Wekerle, H. (2005). The Neuroprotective Effect of Inflammation: Implications for the Therapy of Multiple Sclerosis. In: Perez, H.D., Mitrovic, B., Baron Van Evercooren, A. (eds) Opportunities and Challenges of the Therapies Targeting CNS Regeneration. Ernst Schering Research Foundation Workshop, vol 53. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-27626-2_3
Download citation
DOI: https://doi.org/10.1007/3-540-27626-2_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-24082-2
Online ISBN: 978-3-540-27626-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)